Literature DB >> 17356466

Association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women.

Phyllis C Tien1, Peter Bacchetti, Barbara Gripshover, E Turner Overton, David Rimland, Don Kotler.   

Abstract

OBJECTIVE: Coinfection with hepatitis C virus (HCV) is reported to be associated with a higher prevalence of lipodystrophy than HIV infection alone. We examine the association between HCV and adipose tissue volume in HIV-infected men and women.
METHODS: Cross-sectional analysis of HIV-infected subjects from the study of Fat Redistribution and Metabolic Change in HIV Infection. MRI measured regional adipose tissue volume. Detectable HCV RNA defined HCV infection.
RESULTS: Twenty percent of 792 men and 26% of 329 women were HIV/HCV-coinfected. HIV/HCV-coinfected and HIV-monoinfected women had similar amounts of subcutaneous adipose tissue (SAT) in the leg, lower trunk, upper trunk, and arm and similar amounts of visceral adipose tissue (VAT). Similar findings were seen in men, except in the leg and VAT. After adjustment, HCV infection remained associated with more leg fat in men (12.2%, 95% confidence interval [CI]: 0.3 to 25.3; P = 0.043). Among those on stavudine, HIV-monoinfected men had less leg fat (-7% effect per year of stavudine use, 95% CI: -9 to -5; P < 0.001); a weaker association was seen in HIV/HCV-coinfected men (-2% effect, 95% CI: -7 to 3; P = 0.45). Indinavir was associated with less leg fat (-4% in HIV-monoinfected men, 95% CI: -6 to -1; P = 0.002; -5% in HIV/HCV-coinfected men, 95% CI: -11 to 2; P = 0.14).
CONCLUSIONS: Our findings suggest that HIV/HCV coinfection is not associated with less SAT in men and women. HCV infection seems to mitigate the loss of leg fat seen in HIV-infected men on stavudine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356466      PMCID: PMC3164885          DOI: 10.1097/QAI.0b013e3180423a95

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

1.  Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy?

Authors:  H Zylberberg; B Nalpas; S Pol; C Bréchot; J P Viard
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

2.  Hepatitis C virus in patients with HIV infection and lipodystrophy.

Authors:  Azucena Rodriguez-Guardado; Jose Antonio Maradona; Victor Asensi; Jose Antonio Cartón; Luis Casado
Journal:  J Acquir Immune Defic Syndr       Date:  2003-03-01       Impact factor: 3.731

3.  Volume estimates by imaging methods: model comparisons with visible woman as the reference.

Authors:  Wei Shen; ZiMian Wang; Haiying Tang; Stanley Heshka; Mark Punyanitya; Shankuan Zhu; Jianbo Lei; Steven B Heymsfield
Journal:  Obes Res       Date:  2003-02

4.  Vascular complications associated with use of HIV protease inhibitors.

Authors:  B Gallet; M Pulik; P Genet; P Chedin; M Hiltgen
Journal:  Lancet       Date:  1998-06-27       Impact factor: 79.321

5.  Comparison of two methods of assessing physical activity in the Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Authors:  S Sidney; D R Jacobs; W L Haskell; M A Armstrong; A Dimicco; A Oberman; P J Savage; M L Slattery; B Sternfeld; L Van Horn
Journal:  Am J Epidemiol       Date:  1991-06-15       Impact factor: 4.897

6.  Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.

Authors:  Y Benhamou; V Di Martino; M Bochet; G Colombet; V Thibault; A Liou; C Katlama; T Poynard
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

7.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

8.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

9.  CARDIA: study design, recruitment, and some characteristics of the examined subjects.

Authors:  G D Friedman; G R Cutter; R P Donahue; G H Hughes; S B Hulley; D R Jacobs; K Liu; P J Savage
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

10.  Lack of association of recreational cocaine and alcohol use with left ventricular mass in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) study.

Authors:  G S Hoegerman; C E Lewis; J Flack; J M Raczynski; J Caveny; J M Gardin
Journal:  J Am Coll Cardiol       Date:  1995-03-15       Impact factor: 24.094

View more
  4 in total

Review 1.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

2.  Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals.

Authors:  Phyllis C Tien; Donald P Kotler; E Turner Overton; Cora E Lewis; David Rimland; Peter Bacchetti; Rebecca Scherzer; Barbara Gripshover
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

3.  Metabolic Syndrome in HIV/HCV Co-infected Patients.

Authors:  Lauren F Collins; Ruth O Adekunle; Emily J Cartwright
Journal:  Curr Treat Options Infect Dis       Date:  2019-12-02

4.  New and emerging agents in the management of lipodystrophy in HIV-infected patients.

Authors:  Eric Bonnet
Journal:  HIV AIDS (Auckl)       Date:  2010-09-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.